The efficacy and safety of abatacept in patients with non–life‐threatening manifestations of systemic lupus erythematosus: Results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trial

T. Merrill, Joan; Burgos‐Vargas, Rubén; Westhovens, René; Chalmers, Andrew; D’Cruz, David; J. Wallace, Daniel; Bae, Sang‐Cheol; H. Sigal, Leonard; Becker, Jean‐Claude; Kelly, S.; Raghupathi, Kartik; Li, T.; Peng, Yun; Kinaszczuk, M.; Nash, Peter

doi:10.1002/art.27601

Public

The efficacy and safety of abatacept in patients with non–life‐threatening manifestations of systemic lupus erythematosus: Results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trial

Published in Arthritis & Rheumatism • Jun 8, 2010

Authors:

Joan T. Merrill

Rubén Burgos‐Vargas

René Westhovens

Abstract

OBJECTIVE: To evaluate abatacept therapy in patients with non-life-threatening systemic lupus erythematosus (SLE) and polyarthritis, discoid lesions, or pleuritis and/or pericarditis. METHODS: In a 12-month, multicenter, exploratory, phase IIb randomized, double-blind, placebo-controlled trial, SLE ...

Subject

Medicine

Abatacept

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!